Search Results
1
Study Matches
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa: Phase 2 Double-Blinded to Open-Label Study, up to 60 weeks long. Oral medication, Males/Females 18-75 years old with Hidradenitis Suppurativa (HS) for at least 3 months
Hidradenitis Suppurativa (HS), is a long-lasting, inflammatory skin condition. HS is characterized by lesions that can be found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring.
The purpose of this study is to find out if the study drug, INCB054707 can help treat HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
NCT04476043
Skin Conditions